Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | AMY1A | P0DUB6 | 3/20 | 0.31 |
| ▸ | PDE5A | O76074 | 2/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3011647 | 0.77 | ALDH1A1 (0.34) | IDO1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL352433 | 0.76 | NPC1 (0.36) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL1335301 | 0.74 | NUDT1 (0.37) | DYRK1AMEN1NPC1RAB9AKMT2A | |
| SCHEMBL3877175 | 0.74 | HPGD (0.40) | MEN1NPC1RAB9AKMT2AMAPK13 | |
| SCHEMBL28389415 | 0.72 | DYRK1A (0.34) | DYRK1ANPC1RAB9AKMT2A | |
| SCHEMBL2231635 | 0.70 | MTOR (0.44) | MEN1NPC1RAB9AKMT2AMAPK13 | |
| SCHEMBL11876470 | 0.69 | TRPM8 (0.44) | RAB9A | |
| SCHEMBL9451622 | 0.67 | DGAT1 (0.34) | — | |
| SCHEMBL1335315 | 0.65 | SMN1; SMN2 (0.42) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL5120449 | 0.62 | KDM4E (0.38) | DYRK1AMAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-9873701-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3045458-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2137186-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20150045361-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC (US) | 2015-02-12 | — | — | US | disclosed |
| US-8901135-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2170827-B1 | INDOLIN-2-ONES AND AZA-INDOLIN-2-ONES | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-14 | — | — | EP | disclosed |
| US-8338422-B2 | Indolin-2-ones and aza-indolin-2-ones | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-25 | — | — | US | disclosed |
| US-20120220586-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8193199-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100190786-A1 | INDOLIN-2-ONES AND AZA-INDOLIN-2-ONES | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-29 | — | — | US | disclosed |
| EP-2170827-A2 | INDOLIN-2-ONES AND AZA-INDOLIN-2-ONES | Janssen Pharmaceutica, N.V. (BE) | 2010-04-07 | — | — | EP | disclosed |
| US-20090137581-A1 | Heterocyclic compounds and their uses | AMGEN INC. | 2009-05-28 | — | — | US | disclosed |
| WO-2008155421-A2 | INDOLIN-2-ONES AND AZA-INDOLIN-2-ONES | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-24 | — | — | WO | disclosed |
| US-3988338-A | PLANT GROWTH REGULATORS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | DYRK1A 2146/4885IDO1 266/4885MEN1 1636/4885 |
| US-20090137581-A1 | Heterocyclic compounds and their uses | MCL1, BCL9, MALT1 | DYRK1A 2146/4885IDO1 266/4885MEN1 1636/4885 |
| US-20120220586-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | DYRK1A 2146/4885IDO1 266/4885MEN1 1636/4885 |
| US-20100190786-A1 | INDOLIN-2-ONES AND AZA-INDOLIN-2-ONES | IDO2, IDO1, MKI67 | DYRK1A 182/4885IDO1 2/4885MEN1 1712/4885 |
| US-20150045361-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | DYRK1A 2146/4885IDO1 266/4885MEN1 1636/4885 |
| US-20180105532-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | DYRK1A 2146/4885IDO1 266/4885MEN1 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.